Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.50 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361513 | 0.79 | AR (0.50) | MGLLFAAHAR | |
| SCHEMBL10584544 | 0.76 | TLR9 (0.53) | MGLLFAAHHSP90AA1 | |
| SCHEMBL1363039 | 0.75 | AR (0.63) | AR | |
| SCHEMBL3173897 | 0.74 | AR (0.65) | AR | |
| SCHEMBL13482341 | 0.74 | AR (0.65) | AR | |
| SCHEMBL3173551 | 0.71 | AR (0.71) | AR | |
| SCHEMBL24939818 | 0.70 | PTGS1 (0.54) | MGLLFAAHHSP90AA1 | |
| SCHEMBL10884151 | 0.69 | PTGS1 (0.43) | MGLLFAAHARHSP90AA1 | |
| SCHEMBL6135830 | 0.69 | MGLL (0.68) | MGLLFAAHHSP90AA1 | |
| SCHEMBL95324 | 0.68 | MGLL (1.00) | MGLLFAAHHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655689-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517904-B2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-14 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470797-B2 | Fused heterocyclic imido and amido compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1854798-A2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | Bristol-Myers Squibb Company (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20060264459-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-11-23 | — | — | US | disclosed |
| US-20060223832-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-10-05 | — | — | US | disclosed |
| EP-1458723-A4 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-08 | — | — | US | disclosed |
| US-6953679-B2 | Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050119228-A1 | METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-02 | — | — | US | disclosed |
| EP-1458723-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristols-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119228-A1 | METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF | SUCNR1, SHBG, FSHR | MGLL 4663/4885FAAH 3101/4885AR 36/4885 |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | MGLL 4644/4885FAAH 3122/4885AR 33/4885 |
| US-20060223832-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | MGLL 4644/4885FAAH 3122/4885AR 33/4885 |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | MGLL 4644/4885FAAH 3122/4885AR 33/4885 |
| US-20060264459-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | MGLL 4644/4885FAAH 3122/4885AR 33/4885 |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | MGLL 4644/4885FAAH 3122/4885AR 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.